Brief: Kintor Pharmaceutical Says Clinical Trial Of Pd-L1/Tgf-Β Dual-Targeting Antibody (Gt90008) Approved By NMPA
21/10/2021 14:58
Oct 21 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* CLINICAL TRIAL OF PD-L1/TGF-Β DUAL-TARGETING ANTIBODY
(GT90008)
FOR TREATMENT OF ADVANCED SOLID TUMOURS APPROVED BY NMPA
Source text for Eikon: ID:nHKS8ZKx49
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint